Publication | Closed Access

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

Open-label Phase 2HepatologyHepatitis CViral HepatitisPrevious Null ResponseAntiviral TherapyHepatitisVirologyComplications Of CirrhosisUntreated PatientsLiver DiseaseAntiviral DrugMedicine